2014 Q1 Form 10-K Financial Statement
#000104746914002791 Filed on March 21, 2014
Income Statement
| Concept | 2014 Q1 | 2013 Q4 | 2013 Q3 |
|---|---|---|---|
| Revenue | $9.081M | $10.33M | $1.257M |
| YoY Change | 6077.55% | 848.07% | 1281.32% |
| Cost Of Revenue | $494.0K | $1.100M | $0.00 |
| YoY Change | |||
| Gross Profit | $8.587M | $9.300M | $1.200M |
| YoY Change | 8487.0% | ||
| Gross Profit Margin | 94.56% | 89.99% | 95.47% |
| Selling, General & Admin | $17.53M | $15.20M | $14.60M |
| YoY Change | 29.51% | 74.71% | 258.28% |
| % of Gross Profit | 204.11% | 163.44% | 1216.67% |
| Research & Development | $4.482M | $5.400M | $3.800M |
| YoY Change | -0.88% | 3.85% | -54.25% |
| % of Gross Profit | 52.2% | 58.06% | 316.67% |
| Depreciation & Amortization | $227.0K | $200.0K | $200.0K |
| YoY Change | 40.12% | 0.0% | 29.87% |
| % of Gross Profit | 2.64% | 2.15% | 16.67% |
| Operating Expenses | $22.01M | $20.60M | $18.40M |
| YoY Change | 21.9% | 49.28% | 48.61% |
| Operating Profit | -$13.42M | -$11.30M | -$17.20M |
| YoY Change | -25.05% | 39.95% | |
| Interest Expense | $1.207M | -$2.700M | -$6.900M |
| YoY Change | 66.02% | 237.5% | -884.09% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$2.121M | $0.00 | $0.00 |
| YoY Change | 319.17% | -100.0% | |
| Pretax Income | -$15.50M | -$22.40M | -$24.10M |
| YoY Change | -15.76% | 65.93% | 78.52% |
| Income Tax | $0.00 | $0.00 | $0.00 |
| % Of Pretax Income | |||
| Net Earnings | -$15.54M | -$22.41M | -$24.10M |
| YoY Change | -15.59% | 65.82% | 78.73% |
| Net Earnings / Revenue | -171.16% | -216.82% | -1916.95% |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$370.8K | -$645.5K | -$779.9K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 42.04M shares | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2014 Q1 | 2013 Q4 | 2013 Q3 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $58.90M | $82.20M | $87.20M |
| YoY Change | -15.74% | -7.12% | 43.66% |
| Cash & Equivalents | $12.25M | $32.98M | $22.90M |
| Short-Term Investments | $46.60M | $49.20M | $64.30M |
| Other Short-Term Assets | $2.800M | $2.800M | $2.200M |
| YoY Change | 180.0% | 154.55% | 29.41% |
| Inventory | $7.957M | $7.152M | $5.200M |
| Prepaid Expenses | |||
| Receivables | $9.725M | $5.054M | $7.200M |
| Other Receivables | $700.0K | $0.00 | $1.000M |
| Total Short-Term Assets | $79.93M | $97.16M | $102.9M |
| YoY Change | 4.71% | 6.23% | 63.62% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $2.648M | $2.554M | $2.500M |
| YoY Change | 56.97% | 79.73% | 80.64% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | $2.157M | $1.158M | |
| YoY Change | 244.57% | 69.55% | |
| Long-Term Investments | $11.70M | $8.800M | $15.20M |
| YoY Change | |||
| Other Assets | $360.0K | $361.0K | $2.400M |
| YoY Change | -0.83% | 8.08% | 4263.64% |
| Total Long-Term Assets | $17.59M | $13.83M | $20.90M |
| YoY Change | 544.6% | 447.45% | 406.67% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $79.93M | $97.16M | $102.9M |
| Total Long-Term Assets | $17.59M | $13.83M | $20.90M |
| Total Assets | $97.52M | $111.0M | $123.8M |
| YoY Change | 23.35% | 18.09% | 84.74% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $2.200M | $3.100M | $3.500M |
| YoY Change | -40.54% | -61.25% | -66.67% |
| Accrued Expenses | $12.49M | $15.17M | $11.00M |
| YoY Change | 72.51% | 93.03% | 450.0% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $0.00 | ||
| YoY Change | -100.0% | ||
| Total Short-Term Liabilities | $27.10M | $26.40M | $25.10M |
| YoY Change | 0.35% | 14.87% | 2.07% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $28.40M | $34.40M | $60.20M |
| YoY Change | 255.0% | 209.91% | 326.95% |
| Other Long-Term Liabilities | $2.101M | $2.677M | $26.10M |
| YoY Change | 12.96% | 49.72% | 1575.22% |
| Total Long-Term Liabilities | $2.101M | $2.677M | $86.30M |
| YoY Change | 12.96% | 49.72% | 5439.15% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $27.10M | $26.40M | $25.10M |
| Total Long-Term Liabilities | $2.101M | $2.677M | $86.30M |
| Total Liabilities | $68.51M | $77.53M | $111.3M |
| YoY Change | 81.29% | 112.89% | 162.61% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$194.1M | -$178.5M | |
| YoY Change | 85.41% | 106.98% | |
| Common Stock | $42.00K | $40.00K | |
| YoY Change | 35.48% | 29.03% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $29.01M | $33.46M | $12.50M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $97.52M | $111.0M | $123.8M |
| YoY Change | 23.35% | 18.09% | 84.74% |
Cashflow Statement
| Concept | 2014 Q1 | 2013 Q4 | 2013 Q3 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$15.54M | -$22.41M | -$24.10M |
| YoY Change | -15.59% | 65.82% | 78.73% |
| Depreciation, Depletion And Amortization | $227.0K | $200.0K | $200.0K |
| YoY Change | 40.12% | 0.0% | 29.87% |
| Cash From Operating Activities | -$19.10M | -$9.400M | -$15.50M |
| YoY Change | 10.92% | -41.61% | 37.17% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $263.0K | -$200.0K | -$400.0K |
| YoY Change | -29.3% | 0.0% | 0.0% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$1.400M | $21.10M | $5.000M |
| YoY Change | -50.0% | -331.87% | -150.51% |
| Cash From Investing Activities | -$1.629M | $20.90M | $4.600M |
| YoY Change | -48.27% | -322.34% | -144.66% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $6.000K | ||
| YoY Change | -99.69% | ||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | $5.000K | -1.500M | 0.000 |
| YoY Change | -100.49% | -103.54% | -100.0% |
| NET CHANGE | |||
| Cash From Operating Activities | -$19.10M | -9.400M | -15.50M |
| Cash From Investing Activities | -$1.629M | 20.90M | 4.600M |
| Cash From Financing Activities | $5.000K | -1.500M | 0.000 |
| Net Change In Cash | -$20.73M | 10.00M | -10.90M |
| YoY Change | -3.11% | -40.83% | -54.39% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$19.10M | -$9.400M | -$15.50M |
| Capital Expenditures | $263.0K | -$200.0K | -$400.0K |
| Free Cash Flow | -$19.37M | -$9.200M | -$15.10M |
| YoY Change | 10.07% | -42.14% | 38.53% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2013Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
6081000 | USD |
| CY2011 | us-gaap |
Net Income Loss
NetIncomeLoss
|
53815000 | USD |
| CY2012 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-46284000 | USD |
| CY2011 | us-gaap |
Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
|
74852000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
0 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
59823000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
38222000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | USD |
| CY2013 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
21600000 | USD |
| CY2013Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
9828000 | USD |
| CY2012Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
688000 | USD |
| CY2011Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
752000 | USD |
| CY2010Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
642000 | USD |
| CY2013 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
|
23000 | USD |
| CY2013 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
9117000 | USD |
| CY2012 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
-64000 | USD |
| CY2011 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
110000 | USD |
| CY2013 | supn |
Operating Leases Optional Lease Extension Period
OperatingLeasesOptionalLeaseExtensionPeriod
|
P5Y | |
| CY2013 | supn |
Operating Leases Additional Allowance For Tenant And Capital Improvement
OperatingLeasesAdditionalAllowanceForTenantAndCapitalImprovement
|
1800000 | USD |
| CY2013 | supn |
Operating Leases Allowance For Tenant And Capital Improvement Capitalized
OperatingLeasesAllowanceForTenantAndCapitalImprovementCapitalized
|
500000 | USD |
| CY2011 | supn |
Operating Leases Allowance For Tenant And Capital Improvement Capitalized
OperatingLeasesAllowanceForTenantAndCapitalImprovementCapitalized
|
500000 | USD |
| CY2012 | supn |
Operating Leases Allowance For Tenant And Capital Improvement Capitalized
OperatingLeasesAllowanceForTenantAndCapitalImprovementCapitalized
|
300000 | USD |
| CY2012 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
906000 | USD |
| CY2013 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
1020000 | USD |
| CY2011 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
906000 | USD |
| CY2013 | supn |
Defined Contribution Plan Eligibility Minimum Age
DefinedContributionPlanEligibilityMinimumAge
|
P21Y | |
| CY2013 | us-gaap |
Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
|
0.90 | pure |
| CY2012Q4 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
1090000 | USD |
| CY2012Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
8086000 | USD |
| CY2013 | supn |
Defined Contribution Plan Percentage Vesting Of Employee Contribution
DefinedContributionPlanPercentageVestingOfEmployeeContribution
|
1.00 | pure |
| CY2012Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
9348000 | USD |
| CY2013 | supn |
Defined Contribution Plan Employer Match Level One
DefinedContributionPlanEmployerMatchLevelOne
|
1.00 | pure |
| CY2013 | supn |
Defined Contribution Plan Employer Match Employee Contribution Level One
DefinedContributionPlanEmployerMatchEmployeeContributionLevelOne
|
0.03 | pure |
| CY2013 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
1104000 | USD |
| CY2013Q4 | us-gaap |
Interest Receivable Current
InterestReceivableCurrent
|
483000 | USD |
| CY2012Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
12381000 | USD |
| CY2012Q4 | us-gaap |
Interest Receivable Current
InterestReceivableCurrent
|
664000 | USD |
| CY2013Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2052000 | USD |
| CY2012Q4 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
13834000 | USD |
| CY2012Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
983000 | USD |
| CY2013Q4 | us-gaap |
Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
|
229000 | USD |
| CY2012Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9277000 | USD |
| CY2012Q4 | us-gaap |
Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
|
144000 | USD |
| CY2013 | supn |
Defined Contribution Plan Employer Match Level Two
DefinedContributionPlanEmployerMatchLevelTwo
|
0.50 | pure |
| CY2013 | supn |
Employer Match Employee Contribution Level Two
EmployerMatchEmployeeContributionLevelTwo
|
0.02 | pure |
| CY2013Q4 | us-gaap |
Assets Current
AssetsCurrent
|
97161000 | USD |
| CY2012Q4 | us-gaap |
Assets Current
AssetsCurrent
|
91462000 | USD |
| CY2013 | supn |
Defined Contribution Plan Maximum Discretionary Employer Contribution Percentage
DefinedContributionPlanMaximumDiscretionaryEmployerContributionPercentage
|
0.60 | pure |
| CY2012Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10013000 | USD |
| CY2012 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
323000 | USD |
| CY2013 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
645000 | USD |
| CY2011 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
267000 | USD |
| CY2013Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
361000 | USD |
| CY2012Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
334000 | USD |
| CY2012Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13482000 | USD |
| CY2013Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
147000 | USD |
| CY2013Q4 | us-gaap |
Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
|
1005000 | USD |
| CY2013Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
18055000 | USD |
| CY2012Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13512000 | USD |
| CY2013Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-18414000 | USD |
| CY2012Q4 | us-gaap |
Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
|
89000 | USD |
| CY2013Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.60 | |
| CY2013Q2 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
281000 | USD |
| CY2013Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
15760000 | USD |
| CY2013Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-27357000 | USD |
| CY2012Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-6.05 | |
| CY2013Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.89 | |
| CY2013Q3 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
1257000 | USD |
| CY2012Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.61 | |
| CY2013Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
18432000 | USD |
| CY2012Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.55 | |
| CY2013Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-24096000 | USD |
| CY2013 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
57000 | USD |
| CY2013Q4 | us-gaap |
Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
|
0.0750 | pure |
| CY2012Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.51 | |
| CY2012Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
208000 | USD |
| CY2012Q2 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
91000 | USD |
| CY2013 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b><i>Use of Estimates</i></b></font></p> <p style="FONT-FAMILY: times;"><font size="2">The preparation of the financial statements in accordance with U.S. GAAP requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair value of financial assets and liabilities, common stock options and warrants, income taxes, preclinical study and clinical trial accruals, and other contingencies. Management bases its estimates on historical experience or on various other assumptions, including information received from its service providers and independent valuation consultants, which it believes to be reasonable under the circumstances. Actual results could differ from these estimates.</font></p> </div> | |
| CY2013 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b><i>Concentration of Credit Risk</i></b></font></p> <p style="FONT-FAMILY: times;"><font size="2">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, accounts receivable and marketable securities. The counterparties are various corporations and financial institutions of high credit standing.</font></p> <p style="FONT-FAMILY: times;"><font size="2">Substantially all of the Company's cash and cash equivalents are maintained with well known, U.S. and non U.S. financial institutions, government agencies, and corporations. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, management believes they bear minimal risk.</font></p> </div> | |
| CY2013Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
1118000 | USD |
| CY2013Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
1140000 | USD |
| CY2013Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
1163000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
|
156000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
-63000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-16270000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-13419000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
396000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
57000 | USD |
| CY2013Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.78 | |
| CY2013 | us-gaap |
Revenue Recognition Sales Of Goods
RevenueRecognitionSalesOfGoods
|
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b><i>Revenue Recognition on Product Sales</i></b></font></p> <p style="FONT-FAMILY: times;"><font size="2">Revenue from product sales are recognized when persuasive evidence of an arrangement exists, delivery has occurred and title of the product and associated risk of loss has passed to the customer, the price is fixed or determinable, collection from the customer has been reasonably assured and all performance obligations have been met and returns and allowances can be reasonably estimated. Product sales are recorded net of estimated rebates, chargebacks, discounts, co-pay assistance and other deductions (collectively, "sales deductions") as well as estimated product returns.</font></p> <p style="FONT-FAMILY: times;"><font size="2"><b>Oxtellar XR Gross Revenue</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">The Company launched Oxtellar XR on February 4, 2013. During the fourth quarter of 2013, we began to recognize revenue for Oxtellar XR contemporaneously upon shipment of finished product to wholesalers less allowances for estimated net sales deductions (defined below).</font></p> <p style="FONT-FAMILY: times;"><font size="2"><b>Trokendi XR Gross Revenue</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">Our products are distributed through wholesalers and pharmaceutical distributors. Each of these wholesalers and distributors will take title and ownership of the product upon physical receipt of the product and then distribute our products to the pharmacies. Though these distributors will be invoiced concurrent with product shipment, we will be unable to recognize revenue upon shipment until such time as we can reasonably estimate and record provisions for sales deductions and product returns utilizing historical information and market research projections.</font></p> <p style="FONT-FAMILY: times;"><font size="2">The Company launched Trokendi XR on August 26, 2013. Through December 31, 2013 the Company recorded shipments to wholesalers as deferred revenue i.e., sales price net of known sales deductions (e.g. prompt pay discounts and other similar charges defined below). We lack the experiential data which would allow us to estimate all remaining sales rebates, allowances and returns. Accordingly, we must wait until these data become available to the Company.</font></p> <p style="FONT-FAMILY: times;"><font size="2">Rather than recognize revenue upon shipments to wholesalers, the Company currently recognizes Trokendi XR revenue upon filling prescriptions at pharmacies because prescriptions filled at the pharmacy level have no remaining right of return. However, because we are still compiling historical data related to our experience with other sales deductions, we cannot reasonably estimate all other sales rebates and allowances, but rather must wait until this data becomes available to the Company. Because this occurs approximately eight weeks after the close of the quarter, the Company currently delays recognition of revenue until the subsequent fiscal quarter.</font></p> <p style="FONT-FAMILY: times;"><font size="2">The Company believes the compilation of sufficient product specific historical data to reasonably estimate returns, rebates, and allowances for Trokendi XR may be available by the second quarter of 2014, at which time the Company may record revenue based on shipments to wholesalers rather than on prescriptions filled at the pharmacy level.</font></p> <p style="FONT-FAMILY: times;"><font size="2">With respect to prescriptions which were filled in the third quarter, data on rebates and allowances were generally received by the end of November. As a result of the time lag between the end of the quarter and receipt of these data, the Company could not determine net revenue in a timeframe which would allow reporting third quarter net revenue in the Form 10-Q filed for the quarter ended September 30, 2013. Consequently, revenue generated from prescriptions filled at the pharmacy level in the third quarter are being reported in the Company's fourth quarter financial results. We expect to continue to report revenue based on prescriptions filled at the pharmacy level until sufficient experience with rebates and allowances is assembled to allow reporting of revenue based on shipments to wholesalers.</font></p> <p style="FONT-FAMILY: times;"><font size="2"><b>Net Sales Deductions</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">Allowances for estimated sales deductions are provided for the following:</font></p> <ul> <li style="list-style: none;"> <dl compact="compact"> <dt style="FONT-FAMILY: times; MARGIN-BOTTOM: -11pt;"><font size="2">•</font></dt> <dd style="FONT-FAMILY: times;"><font size="2"><i>Rebates.</i></font><font size="2">  Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, the Medicare coverage gap program, as well as negotiated discounts with commercial health-care providers. Rebates are amounts owed after the final dispensing of products to a benefit plan participant and are based upon contractual agreements or legal requirements with the public sector (e.g. Medicaid) and with private sector benefit providers. The allowance for rebates is based on statutory and contractual discount rates and expected claimed rebates paid based on a plan provider's utilization. Our estimates for expected claimed rebates are based in part on third party market research. Rebates are generally invoiced and paid quarterly in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter's activity, plus an accrual balance for known prior quarters' unpaid rebates. If actual future rebates vary from estimates, we may need to adjust prior period accruals, which would affect revenue in the period of adjustment.</font> <font size="2"><br /> <br /></font></dd> <dt style="FONT-FAMILY: times; MARGIN-BOTTOM: -11pt;"><font size="2">•</font></dt> <dd style="FONT-FAMILY: times;"><font size="2"><i>Chargebacks.</i></font><font size="2">  Chargebacks are discounts that occur when contracted customers purchase directly from an intermediary distributor or wholesaler. Contracted customers, which currently consist primarily of Public Health Service institutions and Federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The distributor or wholesaler, in turn, charges back the difference between the price initially paid by the distributor or wholesaler and the discounted price paid to the distributor or wholesaler by the customer. The allowance for distributor/wholesaler chargebacks is based on known sales to contracted customers.</font> <font size="2"><br /> <br /></font></dd> <dt style="FONT-FAMILY: times; MARGIN-BOTTOM: -11pt;"><font size="2">•</font></dt> <dd style="FONT-FAMILY: times;"><font size="2"><i>Distributor/Wholesaler deductions and discounts.</i></font><font size="2">  U.S. specialty distributors and wholesalers are offered various forms of consideration including allowances, service fees and prompt payment discounts as consideration for distributing our products. Distributor allowances and service fees arise from contractual agreements with distributors and are generally a percentage of the purchase price paid by the distributors and wholesalers. Wholesale customers are offered a prompt pay discount for payment within a specified period.</font> <font size="2"><br /> <br /></font></dd> <dt style="FONT-FAMILY: times; MARGIN-BOTTOM: -11pt;"><font size="2">•</font></dt> <dd style="FONT-FAMILY: times;"><font size="2"><i>Co-pay assistance.</i></font><font size="2">  Patients who pay in cash or have commercial insurance and meet certain eligibility requirements may receive co-pay assistance from the Company. The intent of this program is to reduce the patient's out of pocket costs. Liabilities for co-pay assistance will be based on actual program participation and estimates of program redemption using data provided by third-party administrators.</font> <font size="2"><br /> <br /></font></dd> <dt style="FONT-FAMILY: times; MARGIN-BOTTOM: -11pt;"><font size="2">•</font></dt> <dd style="FONT-FAMILY: times;"><font size="2"><i>Returns.</i></font><font size="2">  Sales of our products are not subject to a general right of return; however, the Company will accept product that is damaged or defective when shipped directly from our warehouse or for expired product up to 12 months subsequent to its expiry date. Product that has been used to fill patient prescriptions is no longer subject to any right of return.</font></dd></dl></li></ul> </div> | |
| CY2013 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | item |
| CY2012 | us-gaap |
Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
|
P10Y | |
| CY2013 | us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
0 | USD |
| CY2012 | us-gaap |
Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
|
1100000 | USD |
| CY2013Q4 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
10334000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-2487000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
18754000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
|
-64000 | USD |
| CY2013Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
57967000 | USD |
| CY2012Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
48259000 | USD |
| CY2013Q4 | supn |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
-33000 | USD |
| CY2012Q4 | supn |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
-1000 | USD |
| CY2013Q4 | supn |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
-33000 | USD |
| CY2012Q4 | supn |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
-54000 | USD |
| CY2013Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
57967000 | USD |
| CY2012Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
48206000 | USD |
| CY2013Q4 | us-gaap |
Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
|
3897000 | USD |
| CY2012Q4 | us-gaap |
Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
|
1152000 | USD |
| CY2013Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
1347000 | USD |
| CY2013Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
1908000 | USD |
| CY2013Q4 | us-gaap |
Inventory Net
InventoryNet
|
7152000 | USD |
| CY2012Q4 | us-gaap |
Inventory Net
InventoryNet
|
1152000 | USD |
| CY2013Q4 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
704000 | USD |
| CY2013Q4 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
1077000 | USD |
| CY2013Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
8145000 | USD |
| CY2012Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
6499000 | USD |
| CY2013Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
5591000 | USD |
| CY2012Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
5078000 | USD |
| CY2013Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2554000 | USD |
| CY2012Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1421000 | USD |
| CY2013 | us-gaap |
Depreciation
Depreciation
|
512000 | USD |
| CY2012 | us-gaap |
Depreciation
Depreciation
|
642000 | USD |
| CY2011 | us-gaap |
Depreciation
Depreciation
|
650000 | USD |
| CY2013Q4 | supn |
Accrued Clinical Trial And Clinical Supply Costs Current
AccruedClinicalTrialAndClinicalSupplyCostsCurrent
|
2253000 | USD |
| CY2012Q4 | supn |
Accrued Clinical Trial And Clinical Supply Costs Current
AccruedClinicalTrialAndClinicalSupplyCostsCurrent
|
3335000 | USD |
| CY2013Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
5016000 | USD |
| CY2012Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
2492000 | USD |
| CY2013Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
619000 | USD |
| CY2012Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
213000 | USD |
| CY2013Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1801000 | USD |
| CY2012Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
505000 | USD |
| CY2013Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
15172000 | USD |
| CY2012Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
7860000 | USD |
| CY2011Q4 | supn |
Subsidiary Or Equity Method Investee Percentage Of Equity Interest Sold
SubsidiaryOrEquityMethodInvesteePercentageOfEquityInterestSold
|
1.00 | pure |
| CY2011 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-2155000 | USD |
| CY2012 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
339000 | USD |
| CY2011 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
-82000 | USD |
| CY2013 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1708000 | USD |
| CY2013Q4 | supn |
Operating Loss Carryforwards Tax Affected
OperatingLossCarryforwardsTaxAffected
|
58000000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | USD |
| CY2011 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
-14090000 | USD |
| CY2011 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
-2155000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-32286000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
340000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-4772000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
31526000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
|
5411000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
|
129000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
|
857000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
-329000 | USD |
| CY2011 | us-gaap |
Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
|
93300000 | USD |
| CY2011 | us-gaap |
Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
|
36800000 | USD |
| CY2013Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
144300000 | USD |
| CY2013Q4 | us-gaap |
Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
|
4200000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
58047000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
32714000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
|
615000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
|
477000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
|
1986000 | USD |
| CY2013Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
|
402000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
|
59000 | USD |
| CY2013Q4 | supn |
Deferred Tax Assets Tax Deferred Expenses Deferred Financing Costs
DeferredTaxAssetsTaxDeferredExpensesDeferredFinancingCosts
|
319000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
|
337000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
|
282000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
4167000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
3901000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
151000 | USD |
| CY2013 | supn |
Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature Net Of Issuance Costs
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeatureNetOfIssuanceCosts
|
21467000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
789000 | USD |
| CY2013Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
5009000 | USD |
| CY2013Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
1186000 | USD |
| CY2013Q4 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
21691000 | USD |
| CY2013Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-22406000 | USD |
| CY2012Q3 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
91000 | USD |
| CY2013 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b>1. Organization and Nature of Operations</b></font></p> <p style="FONT-FAMILY: times;"><font size="2">Supernus Pharmaceuticals, Inc. (the Company) was incorporated in Delaware on March 30, 2005, and commenced operations on December 22, 2005. The Company is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company markets two epilepsy products, Oxtellar XR and Trokendi XR, and has several proprietary product candidates in clinical development that address the attention deficit hyperactivity disorder market.</font></p> <p style="FONT-FAMILY: times;"><font size="2">The Company commenced the commercialization of Oxtellar XR and Trokendi XR in 2013. Oxtellar XR received final approval from the Food and Drug Administration (FDA) on October 19, 2012 and the Company launched this product on February 4, 2013. The Company received final approval from the FDA for Trokendi XR on August 16, 2013 and the Company launched this product on August 26, 2013.</font></p> </div> | |
| CY2013 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2013 | dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | |
| CY2014Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
42044197 | shares |
| CY2013 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2013 | |
| CY2013 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2013 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2013 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2013Q2 | dei |
Entity Public Float
EntityPublicFloat
|
49114520 | USD |
| CY2013 | dei |
Entity Registrant Name
EntityRegistrantName
|
SUPERNUS PHARMACEUTICALS INC | |
| CY2013 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001356576 | |
| CY2013 | dei |
Document Type
DocumentType
|
10-K | |
| CY2013 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2013-12-31 | |
| CY2013 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2013 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
32980000 | USD |
| CY2012Q4 | us-gaap |
Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
|
251000 | USD |
| CY2013Q4 | us-gaap |
Liabilities
Liabilities
|
77531000 | USD |
| CY2012Q4 | us-gaap |
Liabilities
Liabilities
|
36419000 | USD |
| CY2013Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
40000 | USD |
| CY2013 | us-gaap |
Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
|
P10Y | |
| CY2013Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
2292000 | USD |
| CY2012Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
2292000 | USD |
| CY2013Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
1838000 | USD |
| CY2012Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
1609000 | USD |
| CY2013 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
229000 | USD |
| CY2013 | supn |
Finite Lived Intangible Assets Estimated Annual Aggregate Amortization Expense
FiniteLivedIntangibleAssetsEstimatedAnnualAggregateAmortizationExpense
|
229000 | USD |
| CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
40302000 | USD |
| CY2013Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
49211000 | USD |
| CY2012Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
48206000 | USD |
| CY2013Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
5054000 | USD |
| CY2012Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
11000 | USD |
| CY2013Q4 | us-gaap |
Assets
Assets
|
110995000 | USD |
| CY2012Q4 | us-gaap |
Assets
Assets
|
93989000 | USD |
| CY2013Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
18314000 | USD |
| CY2012Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
10666000 | USD |
| CY2013Q4 | supn |
Deferred Product Revenue Net Current
DeferredProductRevenueNetCurrent
|
7882000 | USD |
| CY2013Q4 | supn |
Deferred Revenue Licensing Current
DeferredRevenueLicensingCurrent
|
204000 | USD |
| CY2012Q4 | supn |
Deferred Revenue Licensing Current
DeferredRevenueLicensingCurrent
|
508000 | USD |
| CY2012Q4 | us-gaap |
Secured Debt Current
SecuredDebtCurrent
|
11809000 | USD |
| CY2013Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
26400000 | USD |
| CY2012Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
22983000 | USD |
| CY2013Q4 | supn |
Deferred Revenue Licensing Noncurrent
DeferredRevenueLicensingNoncurrent
|
1417000 | USD |
| CY2012Q4 | supn |
Deferred Revenue Licensing Noncurrent
DeferredRevenueLicensingNoncurrent
|
309000 | USD |
| CY2012Q4 | us-gaap |
Secured Long Term Debt
SecuredLongTermDebt
|
11088000 | USD |
| CY2013Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
2677000 | USD |
| CY2012Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
1788000 | USD |
| CY2013Q4 | us-gaap |
Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
|
12644000 | USD |
| CY2012 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-58000 | USD |
| CY2012Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
31000 | USD |
| CY2013Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
211952000 | USD |
| CY2012Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
143851000 | USD |
| CY2012Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-57000 | USD |
| CY2013Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-178528000 | USD |
| CY2012Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-86255000 | USD |
| CY2013Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
33464000 | USD |
| CY2012Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
57570000 | USD |
| CY2013Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
110995000 | USD |
| CY2012Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
93989000 | USD |
| CY2013Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2012Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2013Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
130000000 | shares |
| CY2012Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
130000000 | shares |
| CY2013Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
39983437 | shares |
| CY2013Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
30621869 | shares |
| CY2012Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
39983437 | shares |
| CY2012Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
30621869 | shares |
| CY2012 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-58000 | USD |
| CY2011 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
1000 | USD |
| CY2011 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
1000 | USD |
| CY2013 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-92216000 | USD |
| CY2012 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-46342000 | USD |
| CY2011 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
53816000 | USD |
| CY2011 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
|
77040000 | USD |
| CY2013 | us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-92273000 | USD |
| CY2012 | us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-46284000 | USD |
| CY2011 | us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-23225000 | USD |
| CY2011 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
25000 | USD |
| CY2013 | us-gaap |
Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
|
-13354000 | USD |
| CY2012 | us-gaap |
Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
|
-710000 | USD |
| CY2011 | us-gaap |
Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
|
-85000 | USD |
| CY2013 | us-gaap |
Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments
|
-57000 | USD |
| CY2012 | us-gaap |
Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments
|
57000 | USD |
| CY2011 | us-gaap |
Marketable Securities Unrealized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments
|
-1000 | USD |
| CY2013 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
742000 | USD |
| CY2012 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
871000 | USD |
| CY2011 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
879000 | USD |
| CY2013 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
3033000 | USD |
| CY2012 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
330000 | USD |
| CY2011 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
218000 | USD |
| CY2013 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1913000 | USD |
| CY2012 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
443000 | USD |
| CY2011 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
-82000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
5043000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
11000 | USD |
| CY2011 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-44000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
|
-181000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
|
664000 | USD |
| CY2011 | us-gaap |
Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
|
-114000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
6000000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1152000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1070000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
516000 | USD |
| CY2011 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
247000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
8492000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-1098000 | USD |
| CY2011 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-959000 | USD |
| CY2013 | supn |
Increase Decrease In Deferred Product Revenue Net
IncreaseDecreaseInDeferredProductRevenueNet
|
7883000 | USD |
| CY2012 | supn |
Increase Decrease In Deferred Licensing Revenue
IncreaseDecreaseInDeferredLicensingRevenue
|
120000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
429000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
109000 | USD |
| CY2011 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
539000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-57949000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-47199000 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-38206000 | USD |
| CY2011 | us-gaap |
Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
|
2021000 | USD |
| CY2011 | supn |
Increase Decrease In Deferred Licensing Revenue
IncreaseDecreaseInDeferredLicensingRevenue
|
697000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-57949000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-47199000 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-36185000 | USD |
| CY2013 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
85567000 | USD |
| CY2012 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
97674000 | USD |
| CY2011 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
17890000 | USD |
| CY2013 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
75806000 | USD |
| CY2012 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
49468000 | USD |
| CY2011 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
26870000 | USD |
| CY2013 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1646000 | USD |
| CY2012 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
753000 | USD |
| CY2011 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
685000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-12112000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-48959000 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
8295000 | USD |
| CY2011 | us-gaap |
Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
|
25607000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-12112000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-48959000 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
33902000 | USD |
| CY2013 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
2437000 | USD |
| CY2012 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
100735000 | USD |
| CY2011 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
29000 | USD |
| CY2011 | us-gaap |
Proceeds From Secured Notes Payable
ProceedsFromSecuredNotesPayable
|
30000000 | USD |
| CY2013 | us-gaap |
Repayments Of Secured Debt
RepaymentsOfSecuredDebt
|
24344000 | USD |
| CY2012 | us-gaap |
Repayments Of Secured Debt
RepaymentsOfSecuredDebt
|
6775000 | USD |
| CY2013 | us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
3627000 | USD |
| CY2012 | us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
6044000 | USD |
| CY2011 | us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
975000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
62739000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
87916000 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
29054000 | USD |
| CY2011 | us-gaap |
Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
|
-1967000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
62739000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
87916000 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
27087000 | USD |
| CY2013 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-7322000 | USD |
| CY2012 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-8242000 | USD |
| CY2011 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
24804000 | USD |
| CY2013 | us-gaap |
Interest Paid
InterestPaid
|
4313000 | USD |
| CY2012 | us-gaap |
Interest Paid
InterestPaid
|
2938000 | USD |
| CY2011 | us-gaap |
Interest Paid
InterestPaid
|
1412000 | USD |
| CY2012 | us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
49000 | USD |
| CY2011 | supn |
Issuance Of Warrant
IssuanceOfWarrant
|
612000 | USD |
| CY2012 | supn |
Exercise Of Warrants Amount Exercised
ExerciseOfWarrantsAmountExercised
|
1156000 | USD |
| CY2013 | supn |
Increase Decrease In Deferred Licensing Revenue
IncreaseDecreaseInDeferredLicensingRevenue
|
803000 | USD |
| CY2011Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
48544000 | USD |
| CY2010Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
23740000 | USD |
| CY2013 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
11552000 | USD |
| CY2013 | us-gaap |
Licenses Revenue
LicensesRevenue
|
467000 | USD |
| CY2013 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
17245000 | USD |
| CY2013 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
55590000 | USD |
| CY2013 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
73939000 | USD |
| CY2013 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-61920000 | USD |
| CY2013 | us-gaap |
Revenues
Revenues
|
12019000 | USD |
| CY2012 | us-gaap |
Licenses Revenue
LicensesRevenue
|
1480000 | USD |
| CY2012 | us-gaap |
Revenues
Revenues
|
1480000 | USD |
| CY2011 | us-gaap |
Licenses Revenue
LicensesRevenue
|
803000 | USD |
| CY2011 | us-gaap |
Revenues
Revenues
|
803000 | USD |
| CY2012 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
23517000 | USD |
| CY2012 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
20132000 | USD |
| CY2012 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
43649000 | USD |
| CY2012 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-42169000 | USD |
| CY2011 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
30627000 | USD |
| CY2011 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
7928000 | USD |
| CY2011 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
38555000 | USD |
| CY2011 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-37752000 | USD |
| CY2013 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
299000 | USD |
| CY2012 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
120000 | USD |
| CY2011 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
31000 | USD |
| CY2013 | us-gaap |
Interest Expense
InterestExpense
|
7849000 | USD |
| CY2012 | us-gaap |
Interest Expense
InterestExpense
|
3575000 | USD |
| CY2011 | us-gaap |
Interest Expense
InterestExpense
|
1866000 | USD |
| CY2013 | us-gaap |
Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
|
-13354000 | USD |
| CY2013 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-9550000 | USD |
| CY2013 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
101000 | USD |
| CY2012 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
50000 | USD |
| CY2011 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
202000 | USD |
| CY2013 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-30353000 | USD |
| CY2012 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-4115000 | USD |
| CY2011 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1718000 | USD |
| CY2013 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-92273000 | USD |
| CY2012 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-46284000 | USD |
| CY2011 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-39470000 | USD |
| CY2011 | us-gaap |
Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
|
2188000 | USD |
| CY2012 | us-gaap |
Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
|
1143000 | USD |
| CY2011 | us-gaap |
Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
|
3430000 | USD |
| CY2013 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-92273000 | USD |
| CY2012 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-47427000 | USD |
| CY2011 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
50385000 | USD |
| CY2013 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-2.90 | |
| CY2013 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.90 | |
| CY2012 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-2.72 | |
| CY2011 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
|
47.99 | |
| CY2011 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
31.39 | |
| CY2013 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
31848299 | shares |
| CY2012 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
17440910 | shares |
| CY2011 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
1605324 | shares |
| CY2010Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-44320000 | USD |
| CY2011 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
-82000 | USD |
| CY2011 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
29000 | USD |
| CY2011Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
9443000 | USD |
| CY2012 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
443000 | USD |
| CY2012 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
223000 | USD |
| CY2012 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
92382000 | USD |
| CY2013 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1913000 | USD |
| CY2013 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
444000 | USD |
| CY2013 | supn |
Sales Return Period
SalesReturnPeriod
|
P12M | |
| CY2011 | us-gaap |
Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
|
30000000 | USD |
| CY2013Q4 | us-gaap |
Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
|
34393000 | USD |
| CY2013Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
1158000 | USD |
| CY2013 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | USD |
| CY2012Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
683000 | USD |
| CY2013Q4 | us-gaap |
Long Term Investments
LongTermInvestments
|
8756000 | USD |
| CY2011 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-16245000 | USD |
| CY2012 | us-gaap |
Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
|
-710000 | USD |
| CY2012 | supn |
Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
|
1156000 | USD |
| CY2012 | supn |
Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
|
265000 | USD |
| CY2013 | supn |
Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
|
78000 | USD |
| CY2011 | us-gaap |
Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
|
-85000 | USD |
| CY2013 | supn |
Stock Issued During Period Value Conversion Of Convertible Notes
StockIssuedDuringPeriodValueConversionOfConvertibleNotes
|
42417000 | USD |
| CY2013 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
869000 | USD |
| CY2013 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
-42417000 | USD |
| CY2013Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
0 | USD |
| CY2012Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
0 | USD |
| CY2012 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | USD |
| CY2013 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
705000 | USD |
| CY2013 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
90000000 | USD |
| CY2011 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
0 | USD |
| CY2012 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
0 | USD |
| CY2013 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
0 | USD |
| CY2013Q4 | us-gaap |
Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
|
79800000 | USD |
| CY2013Q4 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
49211000 | USD |
| CY2012Q4 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
1315000 | USD |
| CY2012Q1 | us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-9277000 | USD |
| CY2012Q2 | us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-10013000 | USD |
| CY2012Q3 | us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-13482000 | USD |
| CY2012Q4 | us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-13512000 | USD |
| CY2013Q1 | us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-17908000 | USD |
| CY2013Q2 | us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-15479000 | USD |
| CY2013Q3 | us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-17175000 | USD |
| CY2013Q4 | us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-11357000 | USD |
| CY2013Q4 | supn |
Deferred Tax Liabilities Debt Discount On Convertible Notes
DeferredTaxLiabilitiesDebtDiscountOnConvertibleNotes
|
6081000 | USD |
| CY2013 | us-gaap |
Revenue Recognition Services Licensing Fees
RevenueRecognitionServicesLicensingFees
|
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b><i>Revenue recognition of License Revenue</i></b></font></p> <p style="FONT-FAMILY: times;"><font size="2"><i>Multiple Element Arrangements</i></font></p> <p style="FONT-FAMILY: times;"><font size="2">For arrangements entered into with multiple elements, such as collaboration agreements, the Company evaluates whether the components of each arrangement are separate elements based on certain criteria. Accordingly, revenues from such agreements are recognized based on the performance requirements of the agreements. The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed and determinable, and collection is reasonably assured.</font></p> <p style="FONT-FAMILY: times;"><font size="2">Non-refundable license fees are recognized as revenue when the Company has a contractual right to receive such payment, the contract price is fixed or determinable, the collection of the resulting receivable is reasonably assured, and the Company has no further significant performance obligations in exchange for the license.</font></p> <p style="FONT-FAMILY: times;"><font size="2">As of January 1, 2011, the Company adopted Accounting Standard Update (ASU) No. 2009-13,</font> <font size="2"><i>Revenue Recognition (Topic 605)—Multiple-Deliverable Revenue Arrangements: a consensus of the FASB Emerging Issues Task Force</i></font> <font size="2">(ASU No. 2009-13) which was codified in ASC 605-25. ASU No. 2009-13 establishes a selling-price hierarchy for determining the selling price of each element within a multiple-deliverable arrangement. Specifically, the selling price assigned to each deliverable is to be based on vendor-specific objective evidence (VSOE) if available; third-party evidence, if VSOE is unavailable; and estimated selling prices if neither VSOE or third-party evidence is available. In addition, ASU No. 2009-13 eliminates the residual method of allocating arrangement consideration and instead requires allocation using the relative selling price method. The adoption of ASU No. 2009-13 did not impact the Company's consolidated financial statements, as the Company did not enter into or modify any multiple element arrangements during 2011. The Company evaluates new or materially modified multiple element arrangements pursuant to the guidance in ASC 605-25.</font></p> <p style="FONT-FAMILY: times;"><font size="2"><i>License and Collaboration Agreements</i></font></p> <p style="FONT-FAMILY: times;"><font size="2">We have entered into collaboration agreements to have both Oxtellar XR and Trokendi XR commercialized outside of the U.S. These agreements generally include an up-front license fee and ongoing milestone payments upon the achievement of specific events. We believe the milestones meet all of the necessary criteria to be considered substantive and therefore should be recognized as revenue when achieved. For up-front license fees, we have estimated the service period of the contract and are recognizing this payment as revenue on a straight-line basis over the respective service period.</font></p> <p style="FONT-FAMILY: times;"><font size="2"><i>Milestone Payments</i></font></p> <p style="FONT-FAMILY: times;"><font size="2">Milestone payments on licensing agreements are recognized as revenue when the collaborative partner acknowledges completion of the milestone and substantive effort was necessary to achieve the milestone. Management may recognize revenue contingent upon the achievement of a milestone in its entirety in the period in which the milestone is achieved only if the milestone meets all the criteria to be considered substantive. Substantive milestone payments are recognized upon achievement of the milestone only if all of the following conditions are met:</font></p> <ul> <li style="list-style: none;"> <dl compact="compact"> <dt style="FONT-FAMILY: times; MARGIN-BOTTOM: -11pt;"><font size="2">•</font></dt> <dd style="FONT-FAMILY: times;"><font size="2">the milestone payments are non-refundable;</font> <font size="2"><br /> <br /></font></dd> <dt style="FONT-FAMILY: times; MARGIN-BOTTOM: -11pt;"><font size="2">•</font></dt> <dd style="FONT-FAMILY: times;"><font size="2">achievement of the milestone involves a degree of risk and was not reasonably assured at the inception of the arrangement;</font> <font size="2"><br /> <br /></font></dd> <dt style="FONT-FAMILY: times; MARGIN-BOTTOM: -11pt;"><font size="2">•</font></dt> <dd style="FONT-FAMILY: times;"><font size="2">substantive effort on the Company's part is involved in achieving the milestone;</font> <font size="2"><br /> <br /></font></dd> <dt style="FONT-FAMILY: times; MARGIN-BOTTOM: -11pt;"><font size="2">•</font></dt> <dd style="FONT-FAMILY: times;"><font size="2">the amount of the milestone payment is reasonable in relation to the effort expended or the risk associated with achievement of the milestone; and</font> <font size="2"><br /> <br /></font></dd> <dt style="FONT-FAMILY: times; MARGIN-BOTTOM: -11pt;"><font size="2">•</font></dt> <dd style="FONT-FAMILY: times;"><font size="2">a reasonable amount of time passes between the up-front license payment and the first milestone payment as well as between each subsequent milestone payment.</font></dd></dl></li></ul> <p style="FONT-FAMILY: times;"><font size="2">Determination as to whether a payment meets the aforementioned conditions involves management's judgment. If any of these conditions are not met, the resulting payment would not be considered a substantive milestone, and therefore the resulting payment would be considered part of the consideration for the single unit of accounting and amortized over the appropriate period.</font></p> <p style="FONT-FAMILY: times;"><font size="2">The Company recorded no milestone revenues during the year ended December, 31, 2013 and $1.1 million of milestone revenue during the year ended December 31, 2012, respectively.</font></p> </div> | |
| CY2013 | us-gaap |
Advertising Cost Policy Expensed Advertising Cost
AdvertisingCostPolicyExpensedAdvertisingCost
|
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="FONT-FAMILY: times;"><font size="2"><b><i>Advertising Expense</i></b></font></p> <p style="FONT-FAMILY: times;"><font size="2">The Company records the cost of its advertising efforts when services are performed or goods are delivered. The Company incurred approximately $14.6 million and $5.8 million in advertising costs for the year ended December 31, 2013 and 2012, respectively.</font></p> </div> | |
| CY2013 | supn |
Number Of Patents Issued
NumberOfPatentsIssued
|
3 | item |
| CY2013Q4 | supn |
Allowance For Expected Prompt Pay Discounts
AllowanceForExpectedPromptPayDiscounts
|
100000 | USD |
| CY2013Q4 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
0 | USD |
| CY2013 | us-gaap |
Advertising Expense
AdvertisingExpense
|
14600000 | USD |
| CY2012 | us-gaap |
Advertising Expense
AdvertisingExpense
|
5800000 | USD |
| CY2013 | supn |
Revenue Recognition Period For Availability Of Requisite Data
RevenueRecognitionPeriodForAvailabilityOfRequisiteData
|
P56D | |
| CY2012Q4 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
0 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
|
282000 | USD |
| CY2013Q4 | supn |
Accrued Rebates And Allowances Current
AccruedRebatesAndAllowancesCurrent
|
1132000 | USD |
| CY2013Q4 | supn |
Accrued Product Costs Current
AccruedProductCostsCurrent
|
3274000 | USD |
| CY2013Q4 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
|
8756000 | USD |
| CY2013 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
57000 | USD |
| CY2013 | supn |
Over Allotment Of Shares During Period Value
OverAllotmentOfSharesDuringPeriodValue
|
1791000 | USD |
| CY2013 | us-gaap |
Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
|
1727000 | USD |
| CY2013 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2012 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2012Q4 | supn |
Allowance For Expected Prompt Pay Discounts
AllowanceForExpectedPromptPayDiscounts
|
0 | USD |
